Merck KGaA announced today that marketing authorization has been granted in Japan for the use of Erbitux® (cetuximab) in treating patients with epidermal growth factor receptor (EGFR)-positive, curatively unresectable (inoperable), advanced or recurrent colorectal cancer (CRC). On the basis of the submitted data, the label allows the use of Erbitux plus irinotecan in second- and further lines of metastatic colorectal cancer (mCRC).*
The details can be read here.
No comments:
Post a Comment